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Background: Including twins in randomised trials leads to non-independence or clustering in the 
data. Clustering has important implications for sample size calculations, yet few trials take this 
into account. Estimates of the intracluster correlation coefficient (ICC), or the correlation between 
outcomes of twins, are needed to assist with sample size planning. Our aims were to provide ICC 
estimates for infant outcomes, describe the information that must be specified in order to account 
for clustering due to twins in sample size calculations, and develop a simple tool for performing 
sample size calculations for trials including twins. 
 
Methods: ICCs were estimated for infant outcomes collected in four randomised trials that 
included twins. The information required to account for clustering due to twins in sample size 
calculations is described. A tool that calculates the sample size based on this information was 
developed in Microsoft Excel and in R as a Shiny web app. 
 
Results: ICC estimates ranged between -0.12, indicating a weak negative relationship, and 0.98, 
indicating a strong positive relationship between outcomes of twins. Example calculations 
illustrate how the ICC estimates and sample size calculator can be used to determine the target 
sample size for trials including twins.  
 
Conclusions: Clustering among outcomes measured on twins should be taken into account in 
sample size calculations to obtain the desired power. Our ICC estimates and sample size calculator 
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will be useful for designing future trials that include twins. Publication of additional ICCs is needed 
to further assist with sample size planning for future trials. 
 






Perinatal trials often include infants from both single and multiple births.1, 2 While 
outcomes measured on singletons can generally be considered independent, outcomes measured 
on infants from a multiple birth tend to be similar due to the shared environment and genetic 
factors.3, 4 Data from these trials are therefore clustered, where each mother or family is a cluster 
and the infants are the members of the cluster.3 The implications of this clustering for the statistical 
analysis of infant outcomes have been widely discussed, with many researchers recommending 
that clustering be taken into account in the analysis whenever multiple births are present.1, 3, 5-7 In 
contrast, the impact of clustering due to multiple births on the sample size calculation has received 
little attention. It is important to account for clustering in sample size calculations to ensure trials 
are appropriately powered, since clustering can reduce the effective sample size.8, 9 However, 
clustering due to multiple births is typically ignored when determining the target sample size for 
perinatal trials.2  
Two main challenges arise when attempting to account for multiple births in sample size 
calculations. Firstly, an estimate of the strength of the dependence between outcomes of infants 
from the same birth is required. This is measured by the intracluster correlation coefficient (ICC), 
which ranges from -1 to 1.9 An ICC of 0 indicates that outcomes of multiples are independent, and 
the ICC approaches 1 or -1 as their outcomes become more positively or negatively correlated, 
respectively. The ICC is rarely reported for trials including multiple births2 and depends on a 
number of factors including the target population, study design, type of intervention, estimation 
method and outcome of interest.10 ICC estimates for a range of infant outcomes from various trials 
are therefore needed to assist with sample size calculations for future trials. Secondly, standard 
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sample size calculation methods assume that the outcomes of all infants are independent. Methods 
have recently been developed that could be used to calculate the sample size for trials including 
multiple births but currently only apply to twins. These methods have been described in the 
statistical literature and involve complex equations.11 To facilitate their use in practice, a more 
user-friendly presentation of the information required to calculate the sample size in the context of 
perinatal trials, and a simple tool for calculating the sample size, are needed.  
In this article we aim to (1) provide ICC estimates for a range of infant outcomes that are 
commonly collected in perinatal trials; (2) describe the  information that must be specified in order 
to account for clustering due to twin births in sample size calculations; and (3) provide a simple 
tool for calculating the target sample size for trials including twin births. Consistent with currently 
available sample size calculation methods,11 we restrict our attention in aims 2 and 3 to trials 
involving singletons and twins, where either mothers or infants are randomised to an intervention 
or control treatment in a 1:1 ratio, and with a continuous or binary primary outcome that will be 
analysed using regression models with generalised estimating equation (GEE) estimation to 
account for clustering due to twins. Other scenarios, including higher order multiples, are 




Estimating intracluster correlation coefficients 
 
 ICCs were estimated using data from four randomised trials that included infants from a 
multiple birth: the Docosahexaenoic Acid for the Improvement of Neurodevelopmental Outcomes 
7 
 
in Preterm Infants (DINO) Trial,12 the Bottles, Cups and Dummies (BCD) Trial,13 the Twins 
Timing of Birth (TTB) Trial14 and the n-3 Fatty Acids for Improvement in Respiratory Outcomes 
(N3RO) Trial.15 The characteristics of these trials are summarised in Table 1 and a more detailed 
description is provided in the Supplementary Material. ICCs were estimated for a range of infant 
outcomes (Tables 2 and 3). Birthweight z-score and small for gestational age were derived using 
Australian standards for singletons and twins,16, 17 and follow-up weight z-score was derived using 
World Health Organization child growth standards.18 
ICCs were estimated in SAS v9.4 using a linear model for continuous variables, and both 
a logistic model and a log binomial model for binary variables. A treatment group effect was 
included in the model for variables measured after randomisation, since ignoring the treatment 
group can lead to biased ICC estimates,19 and a single ICC was estimated across both treatment 
groups. Analyses were performed with and without adjustment for multiple birth status as a fixed 
effect for the three trials that included infants from both single and multiple births, since multiple 
birth status is sometimes used as an adjustment variable in the analysis2 and adjustment can reduce 
the ICC.20 Triplets were included in the analysis for the DINO and N3RO trials but were excluded 
in a sensitivity analysis. Clustering due to multiple births was taken into account using GEEs, as 
this is the most popular estimation method for accounting for this type of clustering 1, 2 and has 
been shown to perform well in this setting.6 ICCs were estimated based on an exchangeable 
working correlation structure (no ICC is estimated if an independence structure is specified) and 
confidence intervals were obtained via bootstrapping using the bias corrected and accelerated 
method21 with resampling of clusters.  
 




 A general approach for determining the target sample size for any study involving clustered 
data begins with calculating the sample size using standard methods that assume all outcomes are 
independent (see e.g.22-24). The resulting sample size is then multiplied by the design effect 
(DEFF), which measures the degree of inflation required to account for clustering in the data. The 
DEFF can be any positive number, with values above and below 1 indicating that a larger or 
smaller sample size is required to account for clustering in the data, respectively. The formula for 
the DEFF varies depending on the setting. For randomised trials including twins, DEFF equations 
have been published elsewhere11 and several design features and parameter estimates must be 
specified in order to calculate the relevant DEFF. First, the method for randomising twins needs 
to be decided. If the mother is to receive the treatment then both twins will necessarily be 
randomised to the same group. If the infant is to receive the treatment then twins may be 
randomised to the same group (cluster randomisation), independently of each other (individual 
randomisation) or to opposite treatment groups. Second, the primary outcome needs to be defined, 
including whether it will be a binary (e.g. neonatal morbidity) or continuous measure (e.g. weight). 
For binary outcomes, the expected outcome prevalence in each treatment group and the effect 
measure of interest (odds ratio or relative risk, estimated by the logistic or log binomial model, 
respectively) must also be specified. Third, the approach that will be used to account for clustering 
in the statistical analysis needs to be chosen. We have focused on GEEs and a simple introduction 
to this estimation method can be found elsewhere.25 It requires specification of an assumed pattern 
of correlation among outcomes for each cluster known as a working correlation structure, and an 
independence or exchangeable working correlation structure may be chosen for analysing trials 
including twins. The latter estimates the correlation between outcomes of pairs of members from 
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the same cluster, which is assumed to be constant, while the former assumes this correlation is 0 
and accounts for clustering using robust variance estimation.26 Fourth, an estimate of the twin birth 
rate for the trial is required. This will vary depending on the population of interest and estimates 
may be obtained from published trials in similar populations or national birth statistics. Care must 
be taken to distinguish between the percentage of mothers in a trial who give birth to twins, and 
the percentage of infants in a trial who are from a twin birth. For example, in a trial recruiting 100 
pregnant women of whom 10 give birth to twins, 10% of women have a twin birth whereas 18% 
of infants (20 out of 110) are from a twin birth. Either percentage can be used to calculate the 
DEFF using our sample size tool. Finally, an estimate of the ICC among twins is needed for the 
primary outcome.  
Once these factors have been specified, the DEFF can be calculated by hand using the 
appropriate equation11 and used to multiply the sample size obtained assuming independence to 
produce the target sample size accounting for clustering due to twins. Alternatively, we have 
developed a sample size calculator that allows researchers to enter the necessary information into 
a Microsoft Excel worksheet or R Shiny web app that calculates the DEFF and sample size 
automatically. Example sample size calculations were performed using Stata v14.2 (assuming all 








 ICC estimates obtained from the four example trials are presented in Table 2 for continuous 
outcomes and Table 3 for binary outcomes based on a logistic model. Very similar results were 
obtained using a log binomial model (data not shown). ICC estimates were mostly positive and 
ranged between -0.12, indicating a weak negative relationship between outcomes of infants from 
the same birth, and 0.98, indicating a strong positive relationship. Most ICCs were estimated 
imprecisely, as reflected in the relatively wide confidence intervals. Differences in ICC estimates 
for the same outcome across trials were often substantial. For example, ICCs for birthweight 
ranged between 0.47 and 0.82. Means and prevalences of the outcomes also varied between trials, 
highlighting differences in the populations studied. Adjusting for multiple birth status generally 
made little difference to the ICC estimates, while excluding triplets typically resulted in slightly 
larger ICC estimates (see Supplementary Material).  
 
Sample size calculator 
 
A sample size tool that calculates the DEFF and target sample size for randomised trials 
including twins in Microsoft Excel is provided in the Supplementary Material. The calculator is 
also available as an R Shiny web app at https://djprice.shinyapps.io/gee_calculator/ and R code for 
local implementation of the calculator is available at https://github.com/DJPrice10/GEE-Sample-
Size-Calculator (see Supplementary Material for further details). The user must input the 
information required to calculate the DEFF, including the twin birth rate and the ICC. To illustrate 
how this calculator and the ICC estimates can be used to determine the target sample size for a 
future trial, consider the following hypothetical examples. Suppose a trial is planned to assess the 
effect of a new infant formula designed to improve growth in infants born preterm (<37 weeks’ 
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gestation). The primary outcome is weight z-score at 18 months of age and the new formula is 
expected to increase the mean z-score by 0.3 compared with standard infant formula. Assuming 
all infants in the trial will be independent, 235 infants are required per group to have 90% power 
to detect this increase, based on a two-sample t-test (alpha=0.05, standard deviation=1). Suppose, 
however, that 70% of infants recruited are expected to be from a single birth, while 30% are 
expected to be from a twin birth. As the intervention will be given to the infants, all methods of 
randomising twins are possible in this trial. The DEFF was calculated using the sample size 
calculator with an ICC of 0.58 based on the DINO Trial (Table 2), since both this trial and the 
hypothetical trial focus on a preterm population with weight measurements at 18 months. 
Assuming the treatment effect will be estimated using GEEs with an independence working 
correlation structure, the target sample size varies from 195 infants per group if twins are assigned 
to opposite treatment groups, to 276 infants per group if cluster randomisation is chosen (see 
Supplementary Material).  
As a second example, suppose another trial is planned to assess the effect of a dietary 
intervention given to pregnant women on the percentage of infants born small for gestational age, 
where the intervention is expected to reduce this from 10% to 5%. Assuming all infants in the trial 
will be independent, 621 infants are required per group based on a two-sided continuity-corrected 
chi-square test (90% power, alpha=0.05). However, 90% of women recruited are expected to have 
a single birth, while 10% are expected to have a twin birth. As the intervention will be given to 
pregnant women, the trial will necessarily use cluster randomisation for twins. The target 
population for the hypothetical trial is somewhat different to the population included in the four 
example trials and hence the largest ICC estimate for being small for gestational age across the 
four trials of 0.36 (Table 3) was chosen to produce the largest sample size, which is most likely to 
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provide adequate power. Using the sample size calculator, the target sample size increases to 662 
or 653 infants per group if the analysis will be performed assuming an independence or 
exchangeable working correlation structure respectively, independent of whether the odds ratio or 
relative risk is the effect measure of interest (see Supplementary Material). 
To understand the impact of twins on sample size calculations more generally, the 
relationship between the ICC and the DEFF is shown in Figure 1, and the relationship between the 
ICC and the sample size is shown in the Supplementary Material. When the twin birth rate is 3%, 
which may be expected in the general population of pregnant women,27 the DEFF is close to 1 and 
hence twins have little impact on the sample size unless the ICC is relatively large (Figure 1A). 
For a twin birth rate of 20%, which is typical in trials targeting preterm infants,2 even a small ICC 
can lead to a DEFF that is substantially different from 1 and hence twins can have a large impact 
on the target sample size (Figure 1B). Assuming the ICC is positive, including twins in a trial 
results in a larger sample size for cluster randomisation, and the same or a smaller sample size for 
individual randomisation or randomisation to opposite treatment groups, compared with a trial 
involving singletons only. A larger sample size is required if the independence rather than the 





We provide ICC estimates for a range of routinely collected infant outcomes from four 
randomised trials that included infants from a multiple birth. ICC estimates were generally positive 
and as high as 0.98. We also describe the information that must be specified in order to calculate 
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the DEFF and hence the sample size for randomised trials including twins, and provide a simple 
tool to perform the calculations automatically. Our example sample size calculations demonstrate 




We found substantial variation in ICC estimates between outcomes and across trials, which 
may be due to differences in the outcome measure, study setting, and inclusion/exclusion criteria. 
We also found that confidence intervals for ICC estimates were relatively wide, even for the N3RO 
trial with over 1200 participants, suggesting that quite large sample sizes are required to accurately 
estimate this parameter. This highlights the need for estimates to be published for a range of 
outcomes collected in different trials and larger epidemiological studies performed in varying 
populations, thus allowing the researcher to use the most relevant ICC for sample size planning. 
Importantly, ICC estimates based on twins born at term may not be relevant to twins born preterm, 
and different outcomes will be of greater clinical interest depending on the gestational age range 
and other characteristics of the target population.  
We presented ICCs estimated with and without adjustment for multiple birth status. While 
adjustment made little difference to ICC estimates for most outcomes, it did have a substantial 
impact in some cases. When planning a trial involving both singletons and twins, the sample size 
should be determined using adjusted ICC estimates if the primary analysis will be adjusted for 
twin birth status, and unadjusted ICC estimates otherwise. For trials that will only include twins, 
we suggest basing the sample size on adjusted ICC estimates, or estimates of the ICC obtained 
from datasets that only include twin births.   
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The target sample size can vary considerably depending on how twins will be randomised. 
Assuming the ICC is positive, assigning twins to different treatment groups requires the smallest 
sample size but may make recruitment challenging, since it is the least favoured method among 
parents of twins.28 Cluster randomisation is the most common randomisation approach used in 
perinatal trials,1, 2 is preferred by parents28 and is the only option for treatments given to the mother, 
but it also requires the largest sample size. Where feasible, individual randomisation may provide 
a good compromise by requiring a smaller sample size than cluster randomisation and being more 
acceptable to parents than randomisation to different groups.28 
To calculate the sample size for a trial that will be analysed using regression models with 
GEE estimation, a decision must be made between assuming an independence or exchangeable 
working correlation structure. Although the exchangeable working correlation structure is more 
realistic, requires a smaller sample size11 and may result in a more efficient analysis,29, 30 it is prone 
to convergence problems11 and may not produce treatment effect estimates with a meaningful 
interpretation.31 We therefore recommend assuming an independence working correlation 
structure for sample size planning and analysis. 
When the outcome of interest is binary, the target sample size can vary depending on 
whether the treatment effect of interest is the odds ratio or the relative risk, although differences 
will generally be small. The relative risk is popular due to the ease of interpretation but 
convergence problems can occur when fitting the log binomial model. These can easily be 
overcome using a modified Poisson approach32 that remains valid for clustered data.33 As the log 
binomial and modified Poisson regression models have similar performance when both 
converge,33 we expect sample size calculations based on the log binomial model will provide the 
desired power if the final analysis is performed using modified Poisson regression. 
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Although this study focused on randomised trials including twins, our findings will be 
helpful for sample size planning in other settings. For trials involving higher order multiples, 
ignoring them and using the sample size calculator to account for twins may give a reasonable 
approximation, provided higher order multiples are expected to be rare. Alternatively, new DEFF 
equations could be derived that allow for higher order multiples and this is an important area for 
future research. For observational studies involving twins, the ICC estimates remain relevant but 
the sample size calculator is currently limited to scenarios where the exposure of interest is binary 
with 50% prevalence (as is the case in randomised trials with two treatment groups and a 1:1 
allocation ratio).  
 
Strengths of the study 
 
This study provides ICC estimates for a range of outcomes from multiple trials conducted using 
different methods of randomisation in different populations, thus allowing researchers to choose 
the most relevant ICC estimate for planning future trials. It also provides the first sample size tool 
that can be used to account for twins in sample size calculations automatically.  
 
Limitations of the data 
 
Our study has several limitations. First, zygosity was not considered in the ICC 
calculations, since this information was not collected in the example trials. ICCs may be higher 
for monozygous compared to dizygous twins34 and future studies collecting zygosity could report 
ICCs separately for these subgroups. Second, the sample size calculator assumes the analysis will 
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be performed using regression models with GEE estimation. Further research is needed to 
determine whether the calculator is suitable to use when other analysis approaches are planned, 
such as mixed effects models, due to potential differences in power. Third, we only present ICC 
estimates from four trials and many outcomes were not available for all trials or were based on a 
neurodevelopmental assessment tool that has since been updated. Additional published ICCs are 
needed. Finally, sample size methods for survival and count outcomes were not considered and 




Clustering due to twins should be taken into account in sample size calculations for 
perinatal trials to obtain the desired power. We have shown how to achieve this by multiplying the 
sample size obtained assuming independence by an appropriate DEFF using our calculator. We 
have also reported ICC estimates that can be used to inform the sample size for future trials. 
Publication of ICCs for additional infant outcomes and from a broader range of studies is needed 
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Table 1. Characteristics of four randomised trials that included infants from multiple births 
 DINO Trial12 BCD Trial13 TTB Trial14 N3RO Trial15 
Recruitment period 2001-2005 1996-1999 2003-2010 2012-2015 




Method of randomising twins Cluster Cluster Cluster Individual 
Gestational age <33 weeks’ <34 weeks’ ≥37 weeks’ <29 weeks’ 
Total number of infants  657 319 470 1273 
Singletons, n (%) 436 (66) 237 (74) 0 (0) 9112) 
Twins, n (%) 194 (30) 82 (26) 470 (100) 3306) 
Triplets, n (%) 27 (4) 0 (0) 0 (0) 32 (3) 
DINO, Docosahexaenoic Acid for the Improvement of Neurodevelopmental Outcomes in Preterm Infants; BCD, Bottles, Cups and 




Table 2. Intracluster correlation coefficients for continuous outcomes measured in four randomised trials  




TTB Trial (n=470) N3RO Trial 
(n=1273) 
Birthweight (g)     
Mean (SD), N 1309 (420), 657 1383 (466), 318 2786 (342), 470 919 (238), 1273 
ICC (95% CI) 0.60 (0.45, 0.77) 0.82 (0.59, 1.00) 0.47 (0.35, 0.57) 0.52 (0.40, 0.67) 
Birthweight z-score     
Mean (SD), N -0.06 (0.99), 657 -0.10 (0.97), 318 0.23 (0.92), 470 0.03 (0.97), 1273 
ICC (95% CI) 0.16 (-0.08, 0.39) 0.44 (0.04, 0.84) 0.43 (0.32, 0.52) 0.26 (0.13, 0.42) 
Follow up weight z-scorea     
Mean (SD), N 0.11 (1.24), 598 -0.73 (1.45), 174 -0.24 (1.10), 319 NA 
ICC (95% CI) 0.58 (0.41, 0.79) 0.46 (0.12, 1.00) 0.74 (0.65, 0.82) NA 
Mental development index 
standardized scorea,b 
    
Mean (SD), N 94.76 (16.27), 611 NA NA NA 




index standardized scorea,b 
    
Mean (SD), N 93.35 (15.78), 609 NA NA NA 
ICC (95% CI) 0.30 (0.08, 0.53) NA NA NA 
NA, not applicable due to data not being collected; SD, standard deviation; N, number of infants with available data; ICC, intracluster 
correlation coefficient; CI, confidence interval; DINO, Docosahexaenoic Acid for the Improvement of Neurodevelopmental Outcomes 
in Preterm Infants; BCD, Bottles, Cups and Dummies; TTB, Twins Timing of Birth; N3RO, n-3 Fatty Acids for Improvement in 
Respiratory Outcomes. 
a Measured at 18 months corrected age for the DINO Trial, 6 months post discharge for the BCD Trial (parent report) and 4 months of 
age for the TTB Trial. 





Table 3. Intracluster correlation coefficients for binary outcomes measured in four randomised trials  




TTB Trial (n=470) N3RO Trial 
(n=1273) 
Low birthweight (<2500g)     
Prevalence (%), N 99.9, 657 99.1, 318 20.4, 470 100, 1273 
ICC (95% CI) NA NA 0.23 (0.09, 0.38) NA 
Very low birthweight (<1500g)     
Prevalence (%), N 63.6, 657 60.1, 318 0.0, 470 98.6, 1273 
ICC (95% CI) 0.39 (0.19, 0.58) 0.74 (0.48, 0.94) NA NA 
Small for gestational age 
(birthweight <10th percentile) 
    
Prevalence (%), N 15.6, 630 14.7, 314 5.3, 470 19.6, 1200 
ICC (95% CI) -0.01 (-0.14, 0.19) 0.36 (0.01, 0.93) 0.06 (-0.06, 0.34) 0.03 (-0.06, 0.11) 
Predischarge death     
Prevalence (%), N 2.3, 656 3.8, 319 0.2, 470 6.9, 1273 
ICC (95% CI) 0.00 (-0.04, 0.02) NA NA 0.32 (0.06, 0.74) 
28 
 
Admitted to neonatal intensive 
care unit 
    
Prevalence (%), N 88.4, 655 NA 3.0, 470 NA 
ICC (95% CI) 0.85 (0.50, 1.00) NA 0.26 (-0.02, 0.76) NA 
Any intraventricular 
haemorrhage 
    
Prevalence (%), N 13.6, 656 12.9, 318 NA 31.9, 1210 
ICC (95% CI) 0.24 (0.03, 0.52) 0.10 (-0.09, 0.59) NA 0.17 (0.03, 0.33) 
Intraventricular haemorrhage 
grade 3 or 4 
    
Prevalence (%), N 2.3, 656 2.5, 318 NA 6.2, 1210 
ICC (95% CI) -0.01 (-0.05, 0.01) NA NA 0.07 (-0.04, 0.42) 
Any retinopathy of prematurity     
Prevalence (%), N 22.5, 654 NA NA 44.7, 1203 
ICC (95% CI) 0.68 (0.43, 0.95) NA NA 0.51 (0.35, 0.64) 
29 
 
Retinopathy of prematurity 
grade 3 or higher 
    
Prevalence (%), N 4.7, 654 NA NA 10.4, 1201 
ICC (95% CI) 0.15 (-0.05, 0.80) NA NA 0.28 (0.09, 0.58) 
Any sepsis     
Prevalence (%), N 15.4, 655 NA NA 27.7, 1234 
ICC (95% CI) 0.36 (0.13, 0.63) NA NA 0.25 (0.10, 0.42) 
Proven necrotising 
enterocolitis 
    
Prevalence (%), N 3.2, 656 2.8, 318 0.0, 470 7.7, 1220 
ICC (95% CI) 0.17 (-0.04, 0.95) NA NA 0.08 (-0.07, 0.42) 
Required continuous positive 
airway pressure 
    
Prevalence (%), N 75.6, 655 55.7, 316 0.6, 470 95.4, 1272 
ICC (95% CI) 0.49 (0.29, 0.71) 0.56 (0.22, 0.83) NA 0.21 (-0.02, 0.70) 
30 
 
Required intermittent positive 
pressure ventilation 
    
Prevalence (%), N 52.8, 655 65.5, 316 1.1, 470 78.9, 1272 
ICC (95% CI) 0.68 (0.51, 0.83) 0.98 (0.69, 1.00) NA 0.55 (0.36, 0.79) 
Bronchopulmonary dysplasiaa     
Prevalence (%), N 22.1, 653 NA NA 47.5, 1149 
ICC (95% CI) 0.46 (0.26, 0.72) NA NA 0.33 (0.17, 0.49) 
Discharged home on oxygen     
Prevalence (%), N 10.1, 652 9.7, 319 0.0, 470 NA 
ICC (95% CI) 0.21 (0.02, 0.59) -0.12 (-0.28, 0.00) NA NA 
NA, not applicable due to insufficient number of cases/non-cases or data not being collected; N, number of infants with available data; 
ICC, intracluster correlation coefficient; CI, confidence interval; DINO, Docosahexaenoic Acid for the Improvement of 
Neurodevelopmental Outcomes in Preterm Infants; BCD, Bottles, Cups and Dummies; TTB, Twins Timing of Birth; N3RO, n-3 Fatty 
Acids for Improvement in Respiratory Outcomes. 
a Defined as supplemental oxygen required at 36 weeks’ postmenstrual age for the DINO Trial, and supplemental oxygen and/or 
respiratory support required with an assessment of oxygen saturation at 36 weeks’ postmenstrual age or discharge home, whichever 





 Figure 1. Relationship between the intracluster correlation coefficient (ICC) and the design effect for a continuous outcome by 
method of randomising twins (cluster randomisation, individual randomisation or randomisation to opposite treatment groups) when 
(A) 3% or (B) 20% of mothers have a twin birth. Black and grey lines indicate scenarios where the independence and exchangeable 
working correlation structures will be assumed in the analysis, respectively. 
 
